Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156336 · ClinicalTrials.gov registry record · Phase 4
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
A Phase 4 study, sponsored by Horizons International Peripheral Group.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02156336: Clinical Trial Phase 4 study, sponsored by Horizons International Peripheral Group.
NCT02156336 is a Phase 4 study that was terminated before completion, run by Horizons International Peripheral Group. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02156336, a Phase 4 study, was terminated before completion, sponsored by Horizons International Peripheral Group.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo. Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical animal model of neuropathic pain, the investigators hypothesize that subjects randomized to ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-02-08 |
| Phase | Phase 4 |
Why NCT02156336 stopped before completion
NCT02156336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02156336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02156336 about?
NCT02156336 is a clinical study titled "Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)". The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo. Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical animal model of ne...
What is the current status of trial NCT02156336?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2014-05. Estimated completion is 2017-02-08.
What interventions are being tested in trial NCT02156336?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02156336?
This trial is sponsored by Horizons International Peripheral Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02156336's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia